peoplePerson
Ursula A. Matulonis
Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.
Gynaecologic oncologist who has led trials of PARP inhibitors, bevacizumab combinations and mirvetuximab soravtansine (MIRASOL) in platinum-resistant ovarian cancer.
Role
Chief, Division of Gynecologic Oncology
Institution
Specialisms
Ovarian cancerPARP inhibitorsAntibody-drug conjugates
Profiles
| Title | Journal | Year |
|---|---|---|
| Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer | New England Journal of Medicine | 2023 |
Pages like this
not linked directly; found by shared links- InstitutionStephenson Cancer Center, OU Health
Shares Mirvetuximab soravtansine, Folate receptor alpha, Olaparib, PARP.
- TrialPAOLA-1 / ENGOT-ov25
Shares Society of Gynecologic Oncology, Olaparib, PARP, Ovarian cancer.
- IdeaSequence folate-receptor ADCs by payload class
Shares Mirvetuximab soravtansine, Folate receptor alpha, Ovarian cancer.
- TrialSOLO-1
Shares Olaparib, PARP, Ovarian cancer.
- InstitutionGOG Foundation
Shares MIRASOL / GOG-3045, Mirvetuximab soravtansine, Society of Gynecologic Oncology, Ovarian cancer.
- PersonAmit M. Oza
Shares Olaparib, PARP, Ovarian cancer.
- PairingPARP inhibitor + bevacizumab maintenance (HRD-positive)
Shares Olaparib, PARP, Ovarian cancer.
- PersonAlan Ashworth
Shares Olaparib, PARP, Ovarian cancer.